• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Supernus Pharmaceuticals, Inc. - Common Stock (NQ:SUPN)

    49.51 -1.85 (-3.61%)
    Streaming Delayed Price Updated: 11:32 AM EST, Jan 13, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Supernus Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    News headline image
    Regencell Bioscience (RGC) Stumbles into 2026: 8% Year-End Slide Sparks Technical Caution
    As the final bells rang on the 2025 trading year, investors in Regencell Bioscience (NASDAQ: RGC) were met with a sobering reality check. The Hong Kong-based biotech firm, which has enjoyed a meteoric... 
    Via MarketMinute
    News headline image
    3 Low-Volatility Stocks We’re Skeptical Of
    Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets. 
    Via StockStory
    News headline image
    3 of Wall Street’s Favorite Stocks That Concern Us
    The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
    Via StockStory
    News headline image
    Earnings Scheduled For November 4, 2025 ↗
     
    Via Benzinga
    News headline image
    A Preview Of Supernus Pharmaceuticals's Earnings ↗
     
    Via Benzinga
    News headline image
    Optimism Flows From Pot To Psychedelics: Atai Beckley, Supernus Stocks Rise After Analyst Flags Positive Tailwinds From Trump’s Marijuana Order ↗
    Jefferies sees restrictions around non-recreational psychedelics eventually loosen up. 
    Via Stocktwits
    Topics Cannabis ETFs Government
    News headline image
    Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back ↗
    The sale hints at profit-taking in a stock that’s executing operationally but facing tougher questions about durability and valuation. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    1 Cash-Heavy Stock for Long-Term Investors and 2 We Turn Down
    A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow. 
    Via StockStory
    News headline image
    3 Stocks Under $50 That Concern Us
    The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead. They also usually carry less risk than penny stocks, though they’re not immune to... 
    Via StockStory
    News headline image
    3 Unprofitable Stocks We Find Risky
    Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. 
    Via StockStory
    News headline image
    Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    1 Healthcare Stock Worth Your Attention and 2 Facing Headwinds
    Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 14.4% over... 
    Via StockStory
    Topics Stocks
    News headline image
    Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
    Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Supernus Pharmaceuticals (NASDAQ:SUPN) and... 
    Via StockStory
    Topics Artificial Intelligence Intellectual Property
    News headline image
    This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why ↗
    A healthcare hedge fund just trimmed its biggest holding—right as the company posts a clinical and financial breakout year. 
    Via The Motley Fool
    Topics Regulatory Compliance
    News headline image
    Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally ↗
    A healthcare hedge fund just locked in gains on one of its biggest winners—here’s what that move really signals. 
    Via The Motley Fool
    News headline image
    3 Russell 2000 Stocks Walking a Fine Line
    The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on. However, these companies often come with higher... 
    Via StockStory
    News headline image
    Supernus to Participate in the 2025 Jefferies Global Healthcare Conference in London
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    5 Must-Read Analyst Questions From Supernus Pharmaceuticals’s Q3 Earnings Call
    Supernus Pharmaceuticals reported Q3 results that were above Wall Street’s revenue and profit expectations, but the market reacted negatively, reflecting concerns over execution challenges and forward... 
    Via StockStory
    Topics Earnings
    News headline image
    Why Supernus Pharmaceuticals (SUPN) Shares Are Trading Lower Today
    Shares of specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) fell 16.8% in the morning session after the company's third-quarter 2025 earnings report, as a weak full-year forecast... 
    Via StockStory
    News headline image
    12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
     
    Via Benzinga
    News headline image
    SUPN Q3 Deep Dive: Growth Drivers Offset By Supply Constraints and Integration Costs
    Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) announced better-than-expected revenue in Q3 CY2025, with sales up 9.3% year on year to $192.1 million. On the other hand, the... 
    Via StockStory
    Topics Supply Chain
    News headline image
    Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Strong Q3
    Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q3 CY2025 results exceeding the market’s revenue expectations, with sales up 9.3% year on year to $192.1 million. On the... 
    Via StockStory
    News headline image
    Supernus Announces Third Quarter 2025 Financial Results
    From Supernus Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    Spotting Winners: Royalty Pharma (NASDAQ:RPRX) And Branded Pharmaceuticals Stocks In Q2
    Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Royalty Pharma (NASDAQ:RPRX) and the best... 
    Via StockStory
    Topics Artificial Intelligence Intellectual Property
    News headline image
    10 Health Care Stocks Whale Activity In Today's Session ↗
     
    Via Benzinga
    News headline image
    Supernus Pharmaceuticals (SUPN) Reports Q3: Everything You Need To Know Ahead Of Earnings
    Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be reporting earnings this Tuesday after market hours. Here’s what you need to know. 
    Via StockStory
    Topics Artificial Intelligence
    News headline image
    3 Cash-Producing Stocks That Fall Short
    A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
    Via StockStory
    News headline image
    Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Emerges as a Top Affordable Growth Candidate ↗
    Supernus Pharmaceuticals (SUPN) offers affordable growth with strong EPS, solid financials, and a low P/E ratio, making it a compelling investment opportunity. 
    Via Chartmill
    News headline image
    Deep Dive Into Supernus Pharmaceuticals Stock: Analyst Perspectives (5 Ratings) ↗
     
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.